$ATRS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ANTARES PHARMA, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ANTARES PHARMA, INC.. Get notifications about new insider transactions in ANTARES PHARMA, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 10 2021 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Payment of Exercise | F | 4.39 | 12,045 | 52,878 | 704,886 | 716.9 K to 704.9 K (-1.68 %) |
| May 06 2021 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | M | 1.66 | 40,000 | 66,400 | 0 | |
| May 06 2021 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Buy | M | 1.66 | 40,000 | 66,400 | 542,125 | 502.1 K to 542.1 K (+7.97 %) |
| May 06 2021 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | M | 1.66 | 40,000 | 66,400 | 0 | |
| May 06 2021 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Buy | M | 1.66 | 40,000 | 66,400 | 542,125 | 502.1 K to 542.1 K (+7.97 %) |
| May 03 2021 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | M | 1.66 | 72,669 | 120,631 | 0 | |
| May 03 2021 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Buy | M | 1.66 | 72,669 | 120,631 | 502,125 | 429.5 K to 502.1 K (+16.92 %) |
| Apr 28 2021 | ATRS | ANTARES PHARMA, IN ... | Richardson Peter C | EVP, R&D Chief Medi ... | Option Exercise | A | 4.01 | 59,179 | 237,308 | 59,179 | |
| Mar 12 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | M | 1.12 | 50,000 | 56,000 | 0 | |
| Mar 12 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Sell | S | 4.28 | 50,000 | 214,000 | 224,406 | 274.4 K to 224.4 K (-18.22 %) |
| Mar 12 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | M | 1.12 | 50,000 | 56,000 | 274,406 | 224.4 K to 274.4 K (+22.28 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Payment of Exercise | F | 4.73 | 35,829 | 169,471 | 691,001 | 726.8 K to 691 K (-4.93 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Grant | A | 0.00 | 80,365 | 0 | 726,830 | 646.5 K to 726.8 K (+12.43 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 0.88 | 250,000 | 220,000 | 0 | |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 2.62 | 5,519 | 14,460 | 0 | |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 5.00 | 241,960 | 1,209,800 | 2,204,760 | 2.4 M to 2.2 M (-9.89 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 5.01 | 17,844 | 89,398 | 2,446,720 | 2.5 M to 2.4 M (-0.72 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 5.00 | 232,156 | 1,160,780 | 2,464,564 | 2.7 M to 2.5 M (-8.61 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 0.88 | 250,000 | 220,000 | 2,696,720 | 2.4 M to 2.7 M (+10.22 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 4.75 | 5,519 | 26,215 | 2,446,720 | 2.5 M to 2.4 M (-0.23 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 2.62 | 5,519 | 14,460 | 2,452,239 | 2.4 M to 2.5 M (+0.23 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 4.73 | 116,313 | 550,160 | 2,446,720 | 2.6 M to 2.4 M (-4.54 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Grant | A | 0.00 | 267,878 | 0 | 2,563,033 | 2.3 M to 2.6 M (+11.67 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 2.24 | 15,321 | 34,319 | 0 | |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 5.05 | 15,321 | 77,371 | 253,042 | 268.4 K to 253 K (-5.71 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 2.24 | 15,321 | 34,319 | 268,363 | 253 K to 268.4 K (+6.05 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Option Exercise | M | 1.12 | 45,000 | 50,400 | 0 | |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Sell | S | 5.05 | 5,000 | 25,250 | 540,417 | 545.4 K to 540.4 K (-0.92 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Sell | S | 4.91 | 40,000 | 196,400 | 545,417 | 585.4 K to 545.4 K (-6.83 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Buy | M | 1.12 | 45,000 | 50,400 | 585,417 | 540.4 K to 585.4 K (+8.33 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 4.73 | 42,073 | 199,005 | 540,417 | 582.5 K to 540.4 K (-7.22 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 0.00 | 80,365 | 0 | 582,490 | 502.1 K to 582.5 K (+16.00 %) |
| Feb 12 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | M | 1.12 | 50,000 | 56,000 | 0 | |
| Feb 12 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Sell | S | 4.62 | 50,000 | 231,000 | 224,406 | 274.4 K to 224.4 K (-18.22 %) |
| Feb 12 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | M | 1.12 | 50,000 | 56,000 | 274,406 | 224.4 K to 274.4 K (+22.28 %) |
| Feb 10 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 2.62 | 7,278 | 19,068 | 0 | |
| Feb 10 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 2.62 | 49,129 | 128,718 | 0 | |
| Feb 10 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 2.62 | 33,574 | 87,964 | 0 | |
| Feb 10 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 4.75 | 7,278 | 34,571 | 2,295,155 | 2.3 M to 2.3 M (-0.32 %) |
| Feb 10 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 2.62 | 7,278 | 19,068 | 2,302,433 | 2.3 M to 2.3 M (+0.32 %) |
| Feb 10 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 4.75 | 49,129 | 233,363 | 2,295,155 | 2.3 M to 2.3 M (-2.10 %) |
| Feb 10 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 2.62 | 49,129 | 128,718 | 2,344,284 | 2.3 M to 2.3 M (+2.14 %) |
| Feb 10 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 4.75 | 33,574 | 159,477 | 2,295,155 | 2.3 M to 2.3 M (-1.44 %) |
| Feb 10 2021 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 2.62 | 33,574 | 87,964 | 2,328,729 | 2.3 M to 2.3 M (+1.46 %) |
| Jan 13 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | M | 1.12 | 50,000 | 56,000 | 0 | |
| Jan 13 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | M | 2.24 | 20,000 | 44,800 | 0 | |
| Jan 13 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Sell | S | 4.05 | 50,000 | 202,500 | 224,406 | 274.4 K to 224.4 K (-18.22 %) |
| Jan 13 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | M | 1.12 | 50,000 | 56,000 | 274,406 | 224.4 K to 274.4 K (+22.28 %) |
| Jan 13 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Sell | S | 4.07 | 20,000 | 81,400 | 224,406 | 244.4 K to 224.4 K (-8.18 %) |
| Jan 13 2021 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | M | 2.24 | 20,000 | 44,800 | 244,406 | 224.4 K to 244.4 K (+8.91 %) |
| Nov 16 2020 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Buy | P | 2.85 | 16,400 | 46,740 | 646,465 | 630.1 K to 646.5 K (+2.60 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Option Exercise | A | 2.73 | 254,165 | 693,870 | 254,165 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Payment of Exercise | F | 2.78 | 8,564 | 23,808 | 630,065 | 638.6 K to 630.1 K (-1.34 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Grant | A | 2.73 | 131,868 | 360,000 | 638,629 | 506.8 K to 638.6 K (+26.02 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | A | 2.73 | 776,617 | 2,120,164 | 776,617 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 2.78 | 40,892 | 113,680 | 2,295,155 | 2.3 M to 2.3 M (-1.75 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Grant | A | 2.73 | 402,930 | 1,099,999 | 2,336,047 | 1.9 M to 2.3 M (+20.84 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Option Exercise | A | 2.73 | 254,165 | 693,870 | 254,165 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.78 | 15,036 | 41,800 | 502,125 | 517.2 K to 502.1 K (-2.91 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 2.73 | 131,868 | 360,000 | 517,161 | 385.3 K to 517.2 K (+34.23 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | A | 2.73 | 77,662 | 212,017 | 77,662 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Grant | A | 2.73 | 40,293 | 110,000 | 253,042 | 212.7 K to 253 K (+18.94 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Option Exercise | A | 2.73 | 58,246 | 159,012 | 58,246 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Grant | A | 2.73 | 30,220 | 82,501 | 54,193 | 24 K to 54.2 K (+126.06 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | A | 2.73 | 58,246 | 159,012 | 58,246 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Grant | A | 2.73 | 30,220 | 82,501 | 429,456 | 399.2 K to 429.5 K (+7.57 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Option Exercise | A | 2.73 | 58,246 | 159,012 | 58,246 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Grant | A | 2.73 | 30,220 | 82,501 | 142,365 | 112.1 K to 142.4 K (+26.95 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | A | 2.73 | 58,246 | 159,012 | 58,246 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Grant | A | 2.73 | 30,220 | 82,501 | 224,406 | 194.2 K to 224.4 K (+15.56 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Option Exercise | A | 2.73 | 58,246 | 159,012 | 58,246 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Grant | A | 2.73 | 30,220 | 82,501 | 54,193 | 24 K to 54.2 K (+126.06 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Option Exercise | A | 2.73 | 58,246 | 159,012 | 58,246 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Grant | A | 2.73 | 30,220 | 82,501 | 54,193 | 24 K to 54.2 K (+126.06 %) |
| Jun 09 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 3.13 | 16,261 | 50,897 | 385,293 | 401.6 K to 385.3 K (-4.05 %) |
| Jun 09 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 3.12 | 17,994 | 56,141 | 401,554 | 419.5 K to 401.6 K (-4.29 %) |
| Jun 09 2020 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Payment of Exercise | F | 3.13 | 8,683 | 27,178 | 506,761 | 515.4 K to 506.8 K (-1.68 %) |
| Jun 09 2020 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Payment of Exercise | F | 3.12 | 9,609 | 29,980 | 515,444 | 525.1 K to 515.4 K (-1.83 %) |
| Jun 09 2020 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 3.13 | 44,223 | 138,418 | 1,933,117 | 2 M to 1.9 M (-2.24 %) |
| Jun 09 2020 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 3.12 | 48,936 | 152,680 | 1,977,340 | 2 M to 2 M (-2.42 %) |
| Feb 21 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 3.53 | 29,947 | 105,713 | 419,548 | 449.5 K to 419.5 K (-6.66 %) |
| Feb 21 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 0.00 | 63,234 | 0 | 449,495 | 386.3 K to 449.5 K (+16.37 %) |
| Feb 21 2020 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Payment of Exercise | F | 3.53 | 23,791 | 83,982 | 525,053 | 548.8 K to 525.1 K (-4.33 %) |
| Feb 21 2020 | ATRS | ANTARES PHARMA, IN ... | Powell Fred M | Executive Vice Pres ... | Grant | A | 0.00 | 63,234 | 0 | 548,844 | 485.6 K to 548.8 K (+13.02 %) |
| Feb 21 2020 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 3.53 | 90,397 | 319,101 | 2,026,276 | 2.1 M to 2 M (-4.27 %) |
| Feb 21 2020 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Grant | A | 0.00 | 210,782 | 0 | 2,116,673 | 1.9 M to 2.1 M (+11.06 %) |
| Jan 14 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | M | 2.66 | 56 | 149 | 0 | |
| Jan 14 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Sell | S | 4.50 | 56 | 252 | 51,751 | 51.8 K to 51.8 K (-0.11 %) |
| Jan 14 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Buy | M | 2.66 | 56 | 149 | 51,807 | 51.8 K to 51.8 K (+0.11 %) |
| Jan 06 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | M | 2.66 | 549 | 1,460 | 0 | |
| Jan 06 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | M | 2.18 | 99,395 | 216,681 | 0 | |
| Jan 06 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Sell | S | 4.60 | 549 | 2,525 | 51,751 | 52.3 K to 51.8 K (-1.05 %) |
| Jan 06 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Buy | M | 2.66 | 549 | 1,460 | 52,300 | 51.8 K to 52.3 K (+1.06 %) |
| Jan 06 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Sell | S | 4.60 | 49,395 | 227,217 | 51,751 | 101.1 K to 51.8 K (-48.84 %) |
| Jan 06 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Buy | M | 2.18 | 49,395 | 107,681 | 101,146 | 51.8 K to 101.1 K (+95.45 %) |
| Jan 06 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Sell | S | 4.59 | 50,000 | 229,500 | 51,751 | 101.8 K to 51.8 K (-49.14 %) |
| Jan 06 2020 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Buy | M | 2.18 | 50,000 | 109,000 | 101,751 | 51.8 K to 101.8 K (+96.62 %) |
| Dec 26 2019 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | M | 1.12 | 150,000 | 168,000 | 0 | |
| Dec 26 2019 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Sell | S | 4.71 | 150,000 | 706,500 | 51,751 | 201.8 K to 51.8 K (-74.35 %) |
| Dec 26 2019 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Buy | M | 1.12 | 150,000 | 168,000 | 201,751 | 51.8 K to 201.8 K (+289.85 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | M | 1.66 | 40,000 | 66,400 | 0 | |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | M | 1.60 | 40,000 | 64,000 | 0 | |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Sell | S | 4.58 | 40,000 | 183,236 | 194,186 | 234.2 K to 194.2 K (-17.08 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | M | 1.66 | 40,000 | 66,400 | 234,186 | 194.2 K to 234.2 K (+20.60 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Sell | S | 4.58 | 40,000 | 183,236 | 194,186 | 234.2 K to 194.2 K (-17.08 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | M | 1.60 | 40,000 | 64,000 | 234,186 | 194.2 K to 234.2 K (+20.60 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 1.66 | 80,000 | 132,800 | 0 | |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 1.60 | 80,000 | 128,000 | 0 | |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 4.63 | 84,814 | 392,833 | 212,749 | 297.6 K to 212.7 K (-28.50 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 4.62 | 80,000 | 369,776 | 297,563 | 377.6 K to 297.6 K (-21.19 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 1.66 | 80,000 | 132,800 | 377,563 | 297.6 K to 377.6 K (+26.89 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Sell | S | 4.63 | 80,000 | 370,536 | 297,563 | 377.6 K to 297.6 K (-21.19 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 1.60 | 80,000 | 128,000 | 377,563 | 297.6 K to 377.6 K (+26.89 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 3.96 | 58,524 | 231,755 | 0 | |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 3.96 | 1,000 | 3,960 | 0 | |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 2.94 | 110,000 | 323,400 | 0 | |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 1.66 | 97,000 | 161,020 | 0 | |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 1.52 | 100,000 | 152,000 | 0 | |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 4.76 | 58,524 | 278,358 | 1,905,891 | 2 M to 1.9 M (-2.98 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 3.96 | 58,524 | 231,755 | 1,964,415 | 1.9 M to 2 M (+3.07 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 4.75 | 1,000 | 4,750 | 1,905,891 | 1.9 M to 1.9 M (-0.05 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 3.96 | 1,000 | 3,960 | 1,906,891 | 1.9 M to 1.9 M (+0.05 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 4.58 | 110,000 | 503,426 | 1,905,891 | 2 M to 1.9 M (-5.46 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 2.94 | 110,000 | 323,400 | 2,015,891 | 1.9 M to 2 M (+5.77 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 4.62 | 97,000 | 448,412 | 1,905,891 | 2 M to 1.9 M (-4.84 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 1.66 | 97,000 | 161,020 | 2,002,891 | 1.9 M to 2 M (+5.09 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Sell | S | 4.68 | 100,000 | 467,830 | 1,905,891 | 2 M to 1.9 M (-4.99 %) |
| Dec 11 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 1.52 | 100,000 | 152,000 | 2,005,891 | 1.9 M to 2 M (+5.25 %) |
| Nov 13 2019 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Gift | G | 3.77 | 25,000 | 94,250 | 51,751 | 76.8 K to 51.8 K (-32.57 %) |
| Nov 13 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Option Exercise | M | 1.10 | 100,000 | 110,000 | 0 | |
| Nov 13 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Payment of Exercise | F | 3.77 | 43,445 | 163,788 | 1,905,891 | 1.9 M to 1.9 M (-2.23 %) |
| Nov 13 2019 | ATRS | ANTARES PHARMA, IN ... | APPLE ROBERT F | President & CEO | Buy | M | 1.10 | 100,000 | 110,000 | 1,949,336 | 1.8 M to 1.9 M (+5.41 %) |
| Nov 04 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | M | 1.10 | 10,000 | 11,000 | 0 | |
| Nov 04 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Buy | M | 1.10 | 10,000 | 11,000 | 194,186 | 184.2 K to 194.2 K (+5.43 %) |
| Nov 04 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | M | 1.10 | 20,000 | 22,000 | 0 | |
| Nov 04 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Buy | M | 1.10 | 20,000 | 22,000 | 297,563 | 277.6 K to 297.6 K (+7.21 %) |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Option Exercise | A | 2.92 | 46,729 | 136,449 | 46,729 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Smith Karen L. | Director | Grant | A | 2.92 | 23,973 | 70,001 | 23,973 | 0 to 24 K |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Option Exercise | A | 2.92 | 46,729 | 136,449 | 46,729 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | Greenleaf Peter | Director | Grant | A | 2.92 | 23,973 | 70,001 | 23,973 | 0 to 24 K |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Option Exercise | A | 2.92 | 46,729 | 136,449 | 46,729 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | SAMSON MARVIN | Director | Grant | A | 2.92 | 23,973 | 70,001 | 76,751 | 52.8 K to 76.8 K (+45.42 %) |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Option Exercise | A | 2.92 | 46,729 | 136,449 | 46,729 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | ROCHE ROBERT P JR | Director | Grant | A | 2.92 | 23,973 | 70,001 | 112,145 | 88.2 K to 112.1 K (+27.19 %) |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Option Exercise | A | 2.92 | 46,729 | 136,449 | 46,729 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | GUETH ANTON | Director | Grant | A | 2.92 | 23,973 | 70,001 | 326,749 | 302.8 K to 326.7 K (+7.92 %) |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Option Exercise | A | 2.92 | 46,729 | 136,449 | 46,729 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | GARRITY THOMAS J | Director | Grant | A | 2.92 | 23,973 | 70,001 | 184,186 | 160.2 K to 184.2 K (+14.96 %) |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Option Exercise | A | 2.92 | 73,431 | 214,419 | 73,431 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | JACOB LEONARD S | Director | Grant | A | 2.92 | 37,671 | 109,999 | 277,563 | 239.9 K to 277.6 K (+15.70 %) |